Regenerative, Gene & Cell Therapies

Progress in regenerative, gene & cell therapies is opening new avenues for restoring lung function at the molecular and structural level. Cell-based interventions, such as mesenchymal stem cells and induced pluripotent stem cells, show promise in modulating inflammation and regenerating damaged alveolar tissue. Gene editing tools like CRISPR-Cas9 are being studied for correcting genetic mutations in disorders such as cystic fibrosis. Regenerative, Gene & Cell Therapies also encompass advances in organoid development, offering scalable disease models and therapeutic platforms. Bioengineered scaffolds and lung-on-chip technologies are aiding translational studies and personalized medicine applications. As safety and efficacy data accumulate from early-phase trials, regulatory agencies and clinical centers are establishing ethical and logistical pathways for wider implementation. This emerging landscape requires collaboration between pulmonologists, molecular biologists, and tissue engineers to shift paradigms in respiratory care.